BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:12 PM
 | 
Jul 07, 2008
 |  BC Extra  |  Company News

NICE issues Tarceva, Tyverb guidance

The U.K.'s NICE issued a preliminary appraisals for Tarceva erlotinib from Roche (SWX:ROG) to treat non-small cell lung cancer (NSCLC) and Tyverb lapatinib from GlaxoSmithKline (LSE:GSK; NYSE:GSK) to treat advanced or metastatic breast cancer.

NICE recommended Tarceva as an alternative to docetaxel as a second-line treatment for NSCLC only when...

Read the full 251 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >